Cosmo Pharmaceuticals N.V. (LON:0RGI)
67.29
-0.21 (-0.31%)
At close: Nov 3, 2025
Cosmo Pharmaceuticals Revenue
Cosmo Pharmaceuticals had revenue of 51.72M EUR in the half year ending June 30, 2025, with 18.46% growth. This brings the company's revenue in the last twelve months to 182.27M, down -1.66% year-over-year. In the year 2024, Cosmo Pharmaceuticals had annual revenue of 266.79M with 187.55% growth.
Revenue (ttm)
182.27M EUR
Revenue Growth
-1.66%
P/S Ratio
6.20
Revenue / Employee
566.41K EUR
Employees
322
Market Cap
968.91M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 266.79M | 174.01M | 187.55% |
| Dec 31, 2023 | 92.78M | -9.31M | -9.12% |
| Dec 31, 2022 | 102.09M | 37.02M | 56.88% |
| Dec 31, 2021 | 65.07M | 4.13M | 6.77% |
| Dec 31, 2020 | 60.95M | -1.55M | -2.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Cosmo Pharmaceuticals News
- 16 days ago - EU Approves Cosmo Pharma' Winlevi For Acne Treatment In Adults And Adolescents - Nasdaq
- 7 months ago - Cosmo Pharmaceuticals ernennt neuen Chief Legal Counsel - Cash
- 8 months ago - Cosmo Pharmaceuticals reports FY results - Seeking Alpha
- 8 months ago - Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and ... - GuruFocus
- 8 months ago - Full Year 2024 Cosmo Pharmaceuticals NV Earnings Call Transcript - GuruFocus
- 10 months ago - Cosmo Pharmaceuticals estimates 186% Y/Y growth in 2024 revenue - Seeking Alpha